- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 59
J-Pharma takes in $16.3m
Osaka University Venture Capital was among the investors in a series D round for Kyorin University-founded cancer treatment developer J-Pharma.
Jul 30, 2020Ceros captures $100m
The cloud-based design platform has raised $100m from new and existing shareholders, but it is unclear if CNF Investments was among those that returned.
Jul 27, 2020Corporate venturing deal net: 20-24 July 2020
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Jul 24, 2020Scalable Capital mounts $58m series D campaign
Scalable Capital is valued in excess of $460m following a round that lifted the digital wealth manager's total funding to about $130m.
Jul 23, 2020Encoded embeds $135m in series D round
GV had led an oversubscribed series D round for the gene therapy developer that also featured Illumina Ventures and SoftBank Vision Fund II.
Jul 23, 2020Scalable Capital mounts $58m series D campaign
Scalable Capital is valued in excess of $460m following a Tengelmann-backed round that lifted the digital wealth manager's total funding to about $130m.
Jul 23, 2020Corporate venturing deal net: 13-17 July 2020
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Jul 17, 2020Coatue comes to Vedantu with $100m
TAL Education-backed online tutoring service Vedantu's Coatue-led series D round increased its valuation from $280m to $600m.
Jul 17, 2020Litte Bear feeds on series D1 funding
IT equipment provider Little Bear Rental will upgrade its partnership with JD.com following the round, where it raised a nine-digit renminbi amount.
Jul 17, 2020Pfizer buys into BioAtla's series D round
Pfizer Ventures, billed as an existing investor, contributed to the $72.5m close of the antibody-drug conjugate developer's latest round.
Jul 16, 2020About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


